Compare AbbVie Inc (ABBV) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Nano Dimension Ltd - ADR — how do they compare? AbbVie Inc trades at $248.03 (market cap $441.94B), while Nano Dimension Ltd - ADR trades at $1.67 (market cap $350.49M). The key difference: AbbVie Inc is far larger — about 1260.9× Nano Dimension Ltd - ADR's market cap, and AbbVie Inc pays a 2.77% dividend while Nano Dimension Ltd - ADR pays none. Which is the better fit depends on your goals.
| ABBV | NNDM | |
|---|---|---|
Market Cap | $441.94B | $350.49M |
Sector | Health | Technology |
52-Week High | $263.58 | $2.14 |
52-Week Low | $197.38 | $1.21 |
Enterprise Value | $506.19B | -$54.35M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
NNDM trades at $1.67, up 2.45% today, with a bullish technical signal from moving averages but overbought RSI levels. The company reported Q2 2026 revenue of $121 million with a net loss of $163 million, reflecting a negative net margin of -135.18%. Recent strategic actions include selling non-core assets to reduce cash burn and appointing an interim CEO amid board restructuring.
The outlook remains challenged by persistent losses and high cash burn, though asset sales may improve liquidity. Investment opportunity hinges on successful execution of cost-saving initiatives and strategic refocusing. Key risks include ongoing operational losses, leadership transitions, and competitive pressures in the additive manufacturing sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
